ଆନିଡୁଲାଫଙ୍ଗିନ

ଆନିଡୁଲାଫଙ୍ଗିନ
Clinical data
Pronunciation	/eɪˌnɪdjʊləˈfʌndʒɪn/ ay-NID-yuu-LƏ-FUN
Trade names	Eraxis, Ecalta, others
Synonyms	(4R,5S)-4,5-Dihydroxy-N2-[[4''-(pentyloxy)-p-terphenyl-4-yl]carbonyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-L-threonyl-(3S,4S)-3-hydroxy-4-methyl-L-proline cyclic (6→1)-peptide; 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4''-(pentyloxy)[1',1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]echinocandin B
AHFS/Drugs.com	monograph
data	EU EMA: yes; US FDA: Anidulafungin;
Pregnancy; category	US: B (No risk in non-human studies) ; ;
Routes of; administration	Intravenous
Legal status
Legal status	℞ (Prescription only);
Pharmacokinetic data
Bioavailability	100% (intravenous use only)
Protein binding	Extensive (>99%)
Metabolism	Liver metabolism not observed, CYP system not involved
Elimination half-life	27 hours; 40–50 hours (terminal)
Excretion	Feces (~30%), urine (<1%)
Identifiers
	IUPAC name N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2R)-1,2-Dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide;
ECHA InfoCard	100.184.856
Chemical and physical data
Formula	C58H73N7O17
Molar mass	୧,୧୪୦.୨୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCOc1ccc(cc1)c2ccc(cc2)c3ccc(cc3)C(=O)N[C@H]6C[C@@H](O)[C@@H](O)NC(=O)C4[C@@H](O)[C@@H](C)CN4C(=O)C(NC(=O)C(NC(=O)C5C[C@@H](O)CN5C(=O)C(NC6=O)[C@@H](C)O)[C@@H](O)[C@H](O)c7ccc(O)cc7)[C@@H](C)O;
	InChI InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42?,43+,44?,45?,46?,47?,48-,49+,50+,54+/m0/s1 ; Key:JHVAMHSQVVQIOT-QZNDWXLFSA-N ;
(verify)

ଆନିଡୁଲାଫଙ୍ଗିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ବେପାର ନାମ ଏରାକ୍ସିସ୍ ଏବଂ ଇକାଲଟା, ହେଉଛି ଏକ କବକବିରୋଧୀ (ଆଣ୍ଟିଫଙ୍ଗାଲ୍) ଔଷଧ ଯାହା ଆକ୍ରମଣକାରୀ କାଣ୍ଡିଡିଆସିସ୍ ଏବଂ ଏସୋଫେଜିଆଲ କ୍ୟାଣ୍ଡିଡିଆସିସ୍ ରୋଫମାନଙ୍କ ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୩] ^[୪] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ଦିଆଯାଏ। | ^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ଅଇ, ଏବଂ କମ୍ ପୋଟାସିୟମ୍ ହୋଇପାରେ ।^[୩] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା ଏବଂ ଆନାଫାଇଲକ୍ସିସ୍ ହୋଇପାରେ । ^[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ଶିଶୁର କ୍ଷତି କରିପାରେ । ^[୪] ଏହା ଏକ ଇକିନୋକାଣ୍ଡିନ ଏବଂ କବକ କୋଷ ପ୍ରାଚୀରର ଏକ ଉପାଦାନ ଉତ୍ପାଦନରେ ହସ୍ତକ୍ଷେପ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୋଇଥାଏ (1 → 3) -βべーた- <small id="mwJQ">D-</small> ଗ୍ଲୁକାନ୍ । ^[୩]

୨୦୦୬ ମସିହାରେ ଆମେରିକାରେ ଏବଂ ୨୦୦୭ରେ ୟୁରୋପରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଆନିଡୁଲାଫଙ୍ଗିନ ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୪] ^[୩] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ। ^[୫] ମିକାଫଙ୍ଗିନର ବିକଳ୍ପ ଭାବରେ ଏହା ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଜରୁରୀ ଔଷଧ ତାଲିକାରେ ଅଛି । ^[୬] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ଏହି ଔଷଧର ମୂଲ୍ୟ ପ୍ରାୟ ୩୦୦ ପାଉଣ୍ଡ ଅଟେ। ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୨୦୦ ଡଲାର ଅଟେ। ^[୭]

ଆଧାର

↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 43" (PDF). World Health Organization. 2000. Archived (PDF) from the original on 18 May 2016. Retrieved 11 November 2016.
↑ "Eraxis (anidulafungin) for Injection, for Intravenous Use. Full Prescribing Information". Roerig (Division of Pfizer, Inc.), New York, NY 10017. Archived from the original on 30 March 2016. Retrieved 11 November 2016.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Ecalta". Archived from the original on 9 August 2021. Retrieved 14 January 2022.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "DailyMed - ERAXIS- anidulafungin injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 14 May 2021. Retrieved 14 January 2022.
↑ ^୫.୦ ^୫.୧ ^୫.୨ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 631. ISBN 978-0857114105.
↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
↑ "Anidulafungin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 14 January 2022.

[INN-1] "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 43" (PDF). World Health Organization. 2000. Archived (PDF) from the original on 18 May 2016. Retrieved 11 November 2016.

[PI-2] "Eraxis (anidulafungin) for Injection, for Intravenous Use. Full Prescribing Information". Roerig (Division of Pfizer, Inc.), New York, NY 10017. Archived from the original on 30 March 2016. Retrieved 11 November 2016.

[EPAR2022-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ "Ecalta". Archived from the original on 9 August 2021. Retrieved 14 January 2022.

[PI2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "DailyMed - ERAXIS- anidulafungin injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 14 May 2021. Retrieved 14 January 2022.

[BNF81-5] ୫.୦ ^୫.୧ ^୫.୨ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 631. ISBN 978-0857114105.

[WHO22nd-6] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[7] "Anidulafungin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 14 January 2022.

[୩]

[୪]

[୫]

[୧]

[୨]

[୬]

[୭]

Clinical data

Pronunciation	/eɪˌnɪdjʊləˈfʌndʒɪn/ ay-NID-yuu-LƏ-FUN
Trade names	Eraxis, Ecalta, others
Synonyms	(4R,5S)-4,5-Dihydroxy-N²-[[4''-(pentyloxy)-p-terphenyl-4-yl]carbonyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-L-threonyl-(3S,4S)-3-hydroxy-4-methyl-L-proline cyclic (6→1)-peptide^[୧] 1-[(4R,5R)-4,5-Dihydroxy-N²-[[4''-(pentyloxy)[1',1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]echinocandin B^[୨]
AHFS/Drugs.com	monograph
data	EU EMA: yes US FDA: Anidulafungin
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	Intravenous
Legal status
Legal status	℞ (Prescription only)
Pharmacokinetic data
Bioavailability	100% (intravenous use only)
Protein binding	Extensive (>99%)
Metabolism	Liver metabolism not observed, CYP system not involved
Elimination half-life	27 hours; 40–50 hours (terminal)
Excretion	Feces (~30%), urine (<1%)
Identifiers
IUPAC name N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2R)-1,2-Dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^9,13]heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide
ECHA InfoCard	100.184.856
Chemical and physical data
Formula	C₅₈H₇₃N₇O₁₇
Molar mass	୧,୧୪୦.୨୫ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCCCCOc1ccc(cc1)c2ccc(cc2)c3ccc(cc3)C(=O)N[C@H]6C[C@@H](O)[C@@H](O)NC(=O)C4[C@@H](O)[C@@H](C)CN4C(=O)C(NC(=O)C(NC(=O)C5C[C@@H](O)CN5C(=O)C(NC6=O)[C@@H](C)O)[C@@H](O)[C@H](O)c7ccc(O)cc7)[C@@H](C)O
InChI InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42?,43+,44?,45?,46?,47?,48-,49+,50+,54+/m0/s1^Y Key:JHVAMHSQVVQIOT-QZNDWXLFSA-N^Y
(verify)